Company intelligence / Profile preview

SEFFILINE

Italy

Ownership: Private
Development stage: Other

Overview

SEFFILINE produces CE certified medical devices enabling autologous regenerative therapies using adipose-derived mesenchymal stem cells. These products are on the market throughout Europe and select other regions, with clinical usage in private and public medical facilities. The technology supports therapies in aesthetic medicine, hair restoration, sports medicine, and gynecological rejuvenation, among others.

Therapeutic areas: Women's HealthOtherDermatologyRheumatology
Modalities: DeviceCell therapyAutologous regenerative therapyMesenchymal stem cell therapy
Industry: Therapeutic Medical Devices

Partnerships

Elite Med Group (exclusive distributor in Switzerland)

Beyond the preview

Go deeper on SEFFILINE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SEFFILINE.

Explore the full profile